EQ - Equillium, Inc.

Insider Sale by Zedelmayer Christine (SVP, COO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 weeks ago, Zedelmayer Christine, serving as SVP, COO at Equillium, Inc. (EQ), sold 185,937 shares at $1.76 per share, for a total transaction value of $328,104.00. Following this transaction, Zedelmayer Christine now holds 91,444 shares of EQ.

This sale represents a 67.00% decrease in Zedelmayer Christine's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, February 19, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 11, 2026, 20 days after the trade was made.

Equillium, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Zedelmayer Christine

SVP, COO

Christine Zedelmayer is a seasoned biopharmaceutical executive serving as Senior Vice President and Chief Operating Officer (SVP, COO) at Equillium, Inc. (NASDAQ: EQ), a clinical-stage biotech company developing treatments for autoimmune and immuno-inflammatory disorders.[[1]](https://fintool.com/app/research/companies/EQ/people/christine-zedelmayer)[[2]](https://biotechvegas.com/people/christine-zedelmayer/)[[3]](https://www.equilliumbio.com/company/board-of-directors/person-details/default.aspx?ItemId=1681c13c-9fba-4b95-a869-c7b46a585d09) She joined Equillium in February 2018 as Vice President of Operations and was promoted to her current role effective January 2020, contributing to key milestones including the company's IPO, IND filing with the FDA, and clinical portfolio execution.[[1]](https://fintool.com/app/research/companies/EQ/people/christine-zedelmayer)[[3]](https://www.equilliumbio.com/company/board-of-directors/person-details/default.aspx?ItemId=1681c13c-9fba-4b95-a869-c7b46a585d09)[[4]](https://www.equilliumbio.com/investors/press-releases/news-details/2019/Equillium-Announces-Leadership-Updates-11-12-2019/default.aspx) Age 55, Zedelmayer recently engaged in insider trading, selling shares on November 25, 2025 (8,098 shares for $7,696) and December 23, 2025 (100,000 shares).[[5]](https://www.investing.com/news/insider-trading-news/equillium-svp-zedelmayer-sells-77k-in-stock-93CH-4378597)[[7]](https://br.tradingview.com/news/tradingview:2b5f53ecc3faf:0-equillium-senior-vp-and-coo-christine-zedelmayer-sells-100-000-shares/) Zedelmayer holds a B.S. in Electrical Engineering from San Diego State University, an MBA in Finance from California Lutheran University, and is a certified Project Management Professional (PMI-PMP).[[1]](https://fintool.com/app/research/companies/EQ/people/christine-zedelmayer)[[3]](https://www.equilliumbio.com/company/board-of-directors/person-details/default.aspx?ItemId=1681c13c-9fba-4b95-a869-c7b46a585d09)[[4]](https://www.equilliumbio.com/investors/press-releases/news-details/2019/Equillium-Announces-Leadership-Updates-11-12-2019/default.aspx) Her career highlights include a 10-year tenure at Amylin Pharmaceuticals as Senior Director of Alliance Management (leading the Eli Lilly collaboration) and Executive Director of Investor Relations, plus engineering and program management roles at Amgen, Ligand Pharmaceuticals, and Hybritech.[[1]](https://fintool.com/app/research/companies/EQ/people/christine-zedelmayer)[[2]](https://biotechvegas.com/people/christine-zedelmayer/)[[3]](https://www.equilliumbio.com/company/board-of-directors/person-details/default.aspx?ItemId=1681c13c-9fba-4b95-a869-c7b46a585d09) From 2012–2018, she was owner/principal at Centerra Consulting, advising life sciences firms on business development and investor relations.[[1]](https://fintool.com/app/research/companies/EQ/people/christine-zedelmayer)[[3]](https://www.equilliumbio.com/company/board-of-directors/person-details/default.aspx?ItemId=1681c13c-9fba-4b95-a869-c7b46a585d09) She currently advises the University of Nevada, Las Vegas Office of Economic Development and has served on advisory boards like DE3.ai.[[1]](https://fintool.com/app/research/companies/EQ/people/christine-zedelmayer)[[2]](https://biotechvegas.com/people/christine-zedelmayer/)

View full insider profile →

Trade Price

$1.76

Quantity

185,937

Total Value

$328,104.00

Shares Owned

91,444

Trade Date

Thursday, February 19, 2026

24 days ago

SEC Filing Date

Wednesday, March 11, 2026

Filed 20 days after trade

HEALTHCAREBIOTECHNOLOGY

About Equillium, Inc.

Company Overview

No company information available
View news mentioning EQ

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4699851

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime